Updated on 2024/11/21

Information

 

写真a

 
KOBAYAKAWA YUKO
 
Organization
Kyushu University Hospital Center for Clinical and Translational Research Information Counter Assistant Professor
School of Medicine Department of Medicine(Concurrent)
Title
Assistant Professor
Profile
ARO次世代医療センター臨床研究推進部門にて、学内外の研究者を対象に臨床試験の計画・実施支援を行い、アカデミア発研究シーズの実用化を推進している。また臨床研究監理部門にて臨床研究の実施や関連規制等についての研修会を行っている。 九州大学病院脳神経内科での診療と、主に筋萎縮性側索硬化症の病態をテーマとした研究活動も行っている。
Homepage
External link

Degree

  • Ph.D.

  • M.D.

Research Interests・Research Keywords

  • Research theme:Disease indicators for amyotrophic lateral sclerosis

    Keyword:Amyotrophic lateral sclerosis

    Research period: 2019.4

Awards

  • 日本臨床試験学会 第15回学術集会総会 最優秀演題賞

    2024.3   日本臨床試験学会   電子的に構造化された臨床試験プロトコル調和テンプレート(CeSHarP,ICH-M11)を模擬分散型臨床試験に使った経験:臨床研究中核病院におけるDCT整備の取組み

  • 第3回日本難病医療ネットワーク学会学術集会 優秀口演賞

    2015.11   日本難病医療ネットワーク学会  

Papers

  • A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial Reviewed International journal

    Hosokawa, K; Watanabe, H; Taniguchi, Y; Ikeda, N; Inami, T; Yasuda, S; Murohara, T; Hatano, M; Tamura, Y; Yamashita, J; Tatsumi, K; Tsujino, I; Kobayakawa, Y; Adachi, S; Yaoita, N; Minatsuki, S; Todaka, K; Fukuda, K; Tsutsui, H; Abe, K

    CIRCULATION   149 ( 5 )   406 - 409   2024.1   ISSN:0009-7322 eISSN:1524-4539

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Circulation  

    DOI: 10.1161/CIRCULATIONAHA.123.067528

    Web of Science

    Scopus

    PubMed

  • A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial. Reviewed International journal

    Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S, Murohara T, Hatano M, Tamura Y, Yamashita J, Tatsumi K, Tsujino I, Kobayakawa Y, Adachi S, Yaoita N, Minatsuki S, Todaka K, Fukuda K, Tsutsui H, Abe K

    Circulation.   149 ( 5 )   406 - 409   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1161/CIRCULATIONAHA.123.067528.

  • A Multicenter, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial Reviewed International journal

    Hosokawa, K; Kishimoto, J; Taniguchi, Y; Ikeda, N; Inami, T; Yasuda, S; Murohara, T; Hatano, M; Tamura, Y; Yamashita, J; Tatsumi, K; Tsujino, I; Kobayakawa, Y; Adachi, S; Yaoita, N; Minatsuki, S; Todaka, K; Fukuda, K; Tsutsui, H; Abe, K

    CIRCULATION   148 ( 25 )   E309 - E309   2023.12   ISSN:0009-7322 eISSN:1524-4539

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Web of Science

  • A novel quantitative indicator for disease progression rate in amyotrophic lateral sclerosis Reviewed International journal

    Kobayakawa, Y; Todaka, K; Hashimoto, Y; Ko, S; Shiraishi, W; Kishimoto, J; Kira, J; Yamasaki, R; Isobe, N

    JOURNAL OF THE NEUROLOGICAL SCIENCES   442   120389   2022.11   ISSN:0022-510X eISSN:1878-5883

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of the Neurological Sciences  

    Objective: The current study sought to develop a new indicator for disease progression rate in amyotrophic lateral sclerosis (ALS). Methods: We used a nonparametric method to score diverse patterns of decline in the percentage of predicted forced vital capacity (%FVC) in patients with ALS. This involved 6317 longitudinal %FVC data sets from 920 patients in the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database volunteered by PRO-ACT Consortium members. To assess the utility of the derived scores as a disease indicator, we examined changes over time, the association with prognosis, and correlation with the Risk Profile of the Treatment Research Initiative to Cure ALS (TRICALS). Our local cohort (n = 92) was used for external validation. Results: We derived scores ranging from 35 to 106 points to construct the FVC Decline Pattern scale (FVC-DiP). Individuals' FVC-DiP scores were determined from a single measurement of %FVC and disease duration at assessment. Although the %FVC declined over the disease course (p < 0.0001), the FVC-DiP remained relatively stable. Low FVC-DiP scores were associated with rapid disease progression. Using our cohort, we demonstrated an association between FVC-DiP and the survival prognosis, the stability of the FVC-DiP per individual, and a correlation between FVC-DiP scores and the TRICALS Risk Profile (r2 = 0.904, p < 0.0001). Conclusions: FVC-DiP scores reflected patterns of declining %FVC over the natural course of ALS and indicated the disease progression rate. The FVC-DiP may enable easy assessment of disease progression patterns and could be used for assessing treatment efficacy.

    DOI: 10.1016/j.jns.2022.120389

    Web of Science

    Scopus

    PubMed

  • A novel quantitative indicator for disease progression rate in amyotrophic lateral sclerosis. Reviewed International journal

    Yuko Kobayakawa, Koji Todaka, Yu Hashimoto, Senri Ko, Wataru Shiraishi, Junji Kishimoto, Jun-Ichi Kira, Ryo Yamasaki, Noriko Isobe

    Journal of the Neurological Sciences   442   120389   2022.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.1016/j.jns.2022.120389

  • Downregulation of neuronal and dendritic connexin36-made electrical synapses without glutamatergic axon terminals in spinal anterior horn cells from the early stage of amyotrophic lateral sclerosis Reviewed International journal

    Kobayakawa Y, Masaki K, Yamasaki R, Shiraishi W, Hayashida S, Hayashi S, Okamoto K, Matsushita T, Kira J

    Frontiers in Neuroscience   12   2018.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fnins.2018.00894

  • Galectin-1 deficiency improves axonal swelling of motor neurons in SOD1G93A transgenic mice Invited Reviewed International journal

    Kobayakawa Y, Sakumi K, Kajitani K, Kadoya T, Horie H, Kira J, Nakabeppu Y

    Neuropathology and Applied Neurobiology   41 ( 2 )   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/nan.12123

  • Characterization of galectin-1-positive cells in the mouse hippocampus Invited Reviewed International journal

    Kajitani K, Kobayakawa Y, Nomaru H, Kadoya T, Horie H, Nakabeppu Y

    NeuroReport   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/WNR.0000000000000068

  • A nationwide survey of facial onset sensory and motor neuronopathy in Japan Reviewed International journal

    Ko, SR; Yamasaki, R; Okui, T; Shiraishi, W; Watanabe, M; Hashimoto, Y; Kobayakawa, Y; Kusunoki, S; Kira, JI; Isobe, N

    JOURNAL OF THE NEUROLOGICAL SCIENCES   459   122957   2024.4   ISSN:0022-510X eISSN:1878-5883

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Journal of the Neurological Sciences  

    The epidemiology and etiology of facial onset sensory and motor neuronopathy (FOSMN), a rare syndrome that initiates with facial sensory disturbances followed by bulbar symptoms, remain unknown. To estimate the prevalence of FOSMN in Japan and establish the characteristics of this disease, we conducted a nationwide epidemiological survey. In the primary survey, we received answers from 604 facilities (49.8%), leading to an estimated number of 35.8 (95% confidential interval: 21.5–50.2) FOSMN cases in Japan. The secondary survey collected detailed clinical and laboratory data from 21 cases. Decreased or absent corneal and pharyngeal reflexes were present in over 85% of the cases. Electrophysiological analyses detected blink reflex test abnormalities in 94.1% of the examined cases. Immunotherapy was administered in 81% of cases and all patients received intravenous immunoglobulin. Among them, 35.3% were judged to have temporary beneficial effects evaluated by the physicians in charge. Immunotherapy tended to be effective in the early stage of disease. The spreading pattern of motor and sensory symptoms differed between cases and the characteristics of the motor-dominant and sensory-dominant cases were distinct. Cases with motor-dominant progression appeared to mimic amyotrophic lateral sclerosis. This is the first nationwide epidemiological survey of FOSMN in Japan. The clinical course of FOSMN is highly variable and motor-dominant cases developed a more severe condition than other types of cases. Because clinical interventions tend to be effective in the early phase of the disease, an early diagnosis is desirable.

    DOI: 10.1016/j.jns.2024.122957

    Web of Science

    Scopus

    PubMed

  • A nationwide survey of facial onset sensory and motor neuronopathy in Japan Reviewed International journal

    Senri Ko, Ryo Yamasaki, Tasuku Okui, Wataru Shiraishi, Mitsuru Watanabe, Yu Hashimoto, Yuko Kobayakawa, Susumu Kusunoki, Jun-ichi Kira h, Noriko Isobe

    J Neurol Sci   459   2024.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: doi: 10.1016/j.jns.2024.122957.

  • 臨床研究のDXに対するARO(Academic Research Organization)の取り組み

    小早川 優子

    神経治療学   41 ( 6 )   S98 - S98   2024   ISSN:09168443 eISSN:21897824

     More details

    Language:Japanese   Publisher:日本神経治療学会  

    DOI: 10.15082/jsnt.41.6_s98

    CiNii Research

  • Natural History and its Association with Inflammatory Markers in Retinitis Pigmentosa: The Protocol of RP PRIMARY Study

    Murakami, Y; Shimokawa, S; Fukushima, M; Hirose, A; Fujiwara, K; Hirata, A; Takada, A; Tokunaga, S; Kobayakawa, Y; Arima, M; Kaida, T; Miyata, K; Mawatari, G; Ishizu, M; Ikeda, Y; Sonoda, KH

    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE   64 ( 8 )   2023.6   ISSN:0146-0404 eISSN:1552-5783

     More details

  • 難病研究会 神経筋疾患を対象とした臨床試験における患者報告アウトカムの利用 患者中心の臨床試験を目指して

    小早川 優子, 磯部 紀子

    難病と在宅ケア   28 ( 10 )   45 - 48   2023.1   ISSN:1880-9200

     More details

    Language:Japanese   Publisher:(株)日本プランニングセンター  

    神経筋疾患を対象とした臨床試験における患者報告アウトカム(Patient-Reported Outcome:PRO)の利用状況を明らかにすることを目的に、グローバルな臨床試験登録データベースであるClinicalTrials.govを用いて、筋萎縮性側索硬化症など神経筋疾患の中でも運動機能障害をきたす代表的な9疾患を対象に検索を行い、評価項目にPROを含む臨床試験(PRO関連臨床試験)の割合について、疾患および期間別に比較した。その結果、最もPRO関連臨床試験数の割合が高い疾患は重症筋無力症で、2017~2021年に開始された臨床試験の約8割で評価項目にPROが使用されていた。一方、PRO関連臨床試験の割合が低い疾患は、筋ジストロフィーおよびハンチントン病で、2017~2021年に開始された臨床試験におけるPRO使用の割合は、いずれも3割以下であった。また、筋萎縮性側索硬化症に対するPRO関連臨床試験について、期間別に検討した結果、2007年~2011年の5年間に比べ2017~2021年の5年間では、PRO関連臨床試験は1.7倍に増加しており、前者の期間ではほとんどの臨床試験で包括的(疾患特異的ではない)PRO尺度が使用されていたが、2012年以降に開始された臨床試験では、約7割で疾患特異的PRO尺度が使用されていることが分かった。

  • Connexin 30 Deficiency Ameliorates Disease Progression at the Early Phase in a Mouse Model of Amyotrophic Lateral Sclerosis by Suppressing Glial Inflammation. Reviewed International journal

    Yu Hashimoto, Ryo Yamasaki, Senri Ko, Eriko Matsuo, Yuko Kobayakawa, Katsuhisa Masaki, Dai Matsuse, Noriko Isobe

    International journal of Molecular Sciences   23 ( 24 )   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.3390/ijms232416046

  • Connexin 30 Deficiency Ameliorates Disease Progression at the Early Phase in a Mouse Model of Amyotrophic Lateral Sclerosis by Suppressing Glial Inflammation Reviewed International journal

    Hashimoto, Y; Yamasaki, R; Ko, SR; Matsuo, E; Kobayakawa, Y; Masaki, K; Matsuse, D; Isobe, N

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES   23 ( 24 )   2022.12   ISSN:16616596 eISSN:1422-0067

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:International Journal of Molecular Sciences  

    Connexin 30 (Cx30), which forms gap junctions between astrocytes, regulates cell adhesion and migration, and modulates glutamate transport. Cx30 is upregulated on activated astroglia in central nervous system inflammatory lesions, including spinal cord lesions in mutant superoxide dismutase 1 (mSOD1) transgenic amyotrophic lateral sclerosis (ALS) model mice. Here, we investigated the role of Cx30 in mSOD1 mice. Cx30 was highly expressed in the pre-onset stage in mSOD1 mice. mSOD1 mice with knockout (KO) of the Cx30 gene (Cx30KO-mSOD1 mice) showed delayed disease onset and tended to have an extended survival period (log-rank, p = 0.09). At the progressive and end stages of the disease, anterior horn cells were significantly preserved in Cx30KO-mSOD1 mice. In lesions of these mice, glial fibrillary acidic protein/C3-positive inflammatory astroglia were decreased. Additionally, the activation of astrocytes in Cx30KO-mSOD1 mice was reduced compared with mSOD1 mice by gene expression microarray. Furthermore, expression of connexin 43 at the pre-onset stage was downregulated in Cx30KO-mSOD1 mice. These findings suggest that reduced expression of astroglial Cx30 at the early disease stage in ALS model mice protects neurons by attenuating astroglial inflammation.

    DOI: 10.3390/ijms232416046

    Web of Science

    Scopus

    PubMed

  • Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial-KABUKI trial Reviewed International journal

    Kazuya Hosokawa, Kohtaro Abe, Junji Kishimoto, Yuko Kobayakawa, Koji Todaka, Yuichi Tamura, Koichiro Tatsumi, Takumi Inami, Nobutaka Ikeda, Yu Taniguchi, Shun Minatsuki, Toyoaki Murohara, Satoshi Yasuda, Keiichi Fukuda, Hiroyuki Tsutsui

    BMJ Open   12 ( 7 )   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: https://doi.org/10.1136/bmjopen-2022-061225

  • Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial-KABUKI trial

    Hosokawa, K; Abe, K; Kishimoto, J; Kobayakawa, Y; Todaka, K; Tamura, Y; Tatsumi, K; Inami, T; Ikeda, N; Taniguchi, Y; Minatsuki, S; Murohara, T; Yasuda, S; Fukuda, K; Tsutsui, H

    BMJ OPEN   12 ( 7 )   e061225   2022.7   ISSN:2044-6055

     More details

    Language:English   Publisher:BMJ Open  

    Introduction Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of prior pulmonary thromboembolism (PE), caused by incomplete clot dissolution after PE. In patients with CTEPH, lifelong anticoagulation is mandatory to prevent recurrence of PE and secondary in situ thrombus formation. Warfarin, a vitamin K antagonist, is commonly used for anticoagulation in CTEPH based on historical experience and evidence. The anticoagulant activity of warfarin is affected by food and drug interactions, requiring regular monitoring of prothrombin time. The lability of anticoagulant effect often results in haemorrhagic and thromboembolic complications. Thus, lifelong warfarin is a handicap in terms of safety and convenience. Currently, the use of direct oral anticoagulants (DOACs) in CTEPH has increased with the advent of four DOACs. The safety of DOACs is superior to warfarin, with less intracranial bleeding in patients with non-valvular atrial fibrillation and venous thromboembolism. Edoxaban, the latest DOAC, also has proven efficacy and safety for those diseases in two large clinical trials; the ENGAGE-AF trial and HOKUSAI-VTE trial. The present trial seeks to evaluate whether edoxaban is non-inferior to warfarin in preventing worsening of CTEPH. Methods and analysis The KABUKI trial (is an investigator-initiated, multicentre, phase 3, randomised, single-blind, parallel-group, warfarin-controlled, non-inferiority trial to evaluate the efficacy and safety of edoxaban versus warfarin (vitamin K Antagonist) in subjects with chronic thromBoembolic pUlmonary hypertension taking warfarin (vitamin K antagonIst) at baseline) is designed to prove the non-inferiority of edoxaban to warfarin in terms of efficacy and safety in patients with CTEPH. Ethics and dissemination This study is approved by the Institutional Review Board of each participating institution. The findings will be published in a peer-reviewed journal, including positive, negative and inconclusive results. Trial registration number NCT04730037. Protocol version This paper was written per the study protocol V.4.0, dated 29 January 2021.

    DOI: 10.1136/bmjopen-2022-061225

    Web of Science

    Scopus

    PubMed

  • DEVELOPMENT OF STANDARDIZED ELISA KITS FOR IGG4 ANTI-NEUROFASCIN 155 AND ANTI-CONTACTIN-1 ANTIBODIES

    Ogata, H; Kobayakawa, Y; Amina, A; Yamasaki, R; Kawasaki, A; Takeuchi, C; Kira, J; Isobe, N

    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM   27   S172 - S172   2022.7   ISSN:1085-9489 eISSN:1529-8027

     More details

  • Clearance of peripheral nerve misfolded mutant protein by infiltrated macrophages correlates with motor neuron disease progression Reviewed International journal

    Shiraishi W, Yamasaki R, Hashimoto Y, Ko S, Kobayakawa Y, Isobe N, Matsushita T, Kira J

    Scientific reports   11 ( 1 )   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/s41598-021-96064-6

  • ALS 医療ニーズと地域医療資源調査~在宅での医療処置や意思伝達装置に焦点をあてて~ Reviewed

    小早川 優子, 岩木 三保, 山﨑 亮, 吉良 潤一

    難病医療ネットワーク学会機関誌   4 ( 2 )   2016.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

Presentations

▼display all

MISC

  • 筋萎縮性側索硬化症の予後を反映した新規分類法の検討

    小早川 優子

    難病と在宅ケア   2021.5

     More details

    Language:Japanese  

  • 難病新法元年を迎えて

    小早川 優子, 吉良 潤一

    日本在宅医学会雑誌   2016.1

     More details

    Language:Japanese  

Professional Memberships

  • 日本神経学会

  • 日本内科学会

  • 日本臨床試験学会

Academic Activities

  • Screening of academic papers

    Role(s): Peer review

    2023

     More details

    Type:Peer review 

    Number of peer-reviewed articles in foreign language journals:1

Research Projects

  • Elucidation of the pathogenesis and identification of novel therapeutic targets using a new scale assessing the clinical diversity of ALS

    Grant number:24K10622  2025 - 2027

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

    CiNii Research

  • (雇用支援)

    2023

    九州大学研究活動基礎支援制度・研究補助者雇用支援(短期)

      More details

    Authorship:Principal investigator  Grant type:On-campus funds, funds, etc.

  • 患者報告アウトカムの取得率及び信頼性向上のためのガイドライン案策定

    2022.8 - 2025.3

      More details

    Authorship:Principal investigator 

  • Detection of ALS origin with reference to calcium-binding proteins, those generate glial inflammation

    Grant number:22K07517  2022.4 - 2025.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant type:Scientific research funding

    CiNii Research

  • 筋萎縮性側索硬化症に対する治療薬開発を促進する新規評価指標の確立

    2022.4 - 2024.3

      More details

    Authorship:Principal investigator 

  • 患者報告アウトカムの取得率及び信頼性向上のためのガイドライン案策定

    2022 - 2025

    日本医療研究開発機構「医薬品等規制調和・評価研究事業」

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • 筋萎縮性側索硬化症に対する治療薬開発を促進する新規評価指標の確立

    2022 - 2023

    公益財団法人難病医学研究財団 令和4年度 医学研究奨励助成事業

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • (雇用支援)

    2022

    九州大学研究活動基礎支援制度・研究補助者雇用支援(短期)

      More details

    Authorship:Principal investigator  Grant type:On-campus funds, funds, etc.

  • (雇用支援)

    2021

    九州大学研究活動基礎支援制度・研究補助者雇用支援(短期)

      More details

    Authorship:Principal investigator  Grant type:On-campus funds, funds, etc.

  • 神経変性疾患の病期に着目した治療法開発および承認後適正使用を推進する新規評価法の確立

    2019.7 - 2022.3

      More details

    Authorship:Principal investigator 

  • 電気シナプスを介する運動神経興奮性制御機構の解明と同シナプス回復によるALS治療

    2019 - 2021

    日本学術振興会  科学研究費助成事業  若手研究

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 神経変性疾患の病期に着目した治療法開発および承認後適正使用を推進する新規評価法の確立

    2019 - 2021

    日本医療研究開発機構「医薬品等規制調和・評価研究事業」

      More details

    Authorship:Principal investigator  Grant type:Contract research

  • 神経難病に対する臨床試験の効率化・適正化の推進

    2019

    研究活動基礎支援制度・出産育児復帰者支援

      More details

    Authorship:Principal investigator  Grant type:On-campus funds, funds, etc.

  • 筋萎縮性側索硬化症における電気シナプス喪失による運動ニューロン死の促進とその制御

    2016 - 2017

    科学研究費助成事業  若手研究(B)

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • オリゴデンドロサイトのコネキシン蛋白に注目したALSの病態解明と神経治療薬の開発

    2014

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

      More details

    Authorship:Principal investigator  Grant type:Scientific research funding

  • 電気シナプスを介する運動神経興奮性制御機構の解明と同シナプス回復によるALS治療

    Grant number:19K17010 

    小早川 優子

      More details

    Grant type:Scientific research funding

    神経細胞間の情報伝達機構には、神経伝達物質がシナプス後膜の受容体に結合する化学シナプスの他に、隣接する神経細胞膜上のConnexin(Cx)蛋白どおしが形成するgap junctionを通じてイオンや小分子が直接細胞間を移動する電気シナプスがある。私たちはこれまでに、筋萎縮性側索硬化症(ALS)モデルマウスの腰髄前角では、電気シナプスを形成する代表的Cx蛋白であるCx36が病初期より減少していることを見出している。本研究では、Cx36が形成する電気シナプスの減少が、脊髄神経細胞の電気活動に及ぼす影響を明らかにし、電気シナプスを標的としたALSの新規治療法開発をめざす。

    CiNii Research

  • 筋萎縮性側索硬化症の脊髄に存在するグリア炎症とガレクチン3、p22の意義と治療

    Grant number:19K07996 

    林 信太郎, 山崎 亮, 小早川 優子

      More details

    Grant type:Scientific research funding

    筋萎縮性側索硬化症は、最重症の神経難病とされる。本疾患が文献で記載され既に1世紀以上が経過したが、現在も原因は不明である。従って、発症前の状態にまで戻せる治療法は存在しない。この理由の1つに発症から確定診断まで平均13ヵ月を要することが指摘されているが、この事は真の病態解明や有効な治療法を開発する上で大きな妨げとなっている。私達は、本疾患の発症初期に関与するグリア炎症関連分子としてガレクチン3とp22という分子を発見した。本研究ではこの両分子に着目し病態を解明するために、発症早期に診断できる検査技術の創出と神経変性疾患に対しては初の分子標的療法の開発を目的とする。

    CiNii Research

▼display all

Outline of Social Contribution and International Cooperation activities

  • 厚生労働省臨床研究総合促進事業「臨床研究・治験従事者等に対する研修プログラム」及び国立大学病院臨床研究推進会議のサブグループ活動への参画により国内の研究者およびARO関係者との連携を図っている。
    アジアオセアニア研究教育機構・医療健康クラスター・満たされない医療モジュールのモジュールメンバーとして、アジアオセアニア地域に特徴的な満たされない医療ニーズを充足すべく、臨床研究基盤整備、臨床試験の実施支援、規制科学研究等を行う。

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Internal Medicine / Neurology

Clinician qualification

  • Specialist

    Japanese Society of Neurology

  • Specialist

    The Japanese Society of Internal Medicine(JSIM)

Year of medical license acquisition

  • 2005